Novartis has announced the US approval of its licensed quadrivalent meningococcal vaccine, Menveo, in children aged two to 10; however, the FDA rejected an application for younger age groups. This represents a major setback for the firm, which is already struggling to gain share in the US meningococcal market due to the dominance of Sanofi Pasteur's competitor Menactra.
Edit my basket
© Datamonitor 2012. All rights reserved
Terms & Conditions